Taltz ® (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Taltz® (ixekizumab): What are the differences between the new and old formulation?

The new citrate-free formulation is without buffers and contains sucrose as tonicity agent.


Formulation differences

The new citrate-free formulation of ixekizumab

  • does not contain any buffer; that is, it is
    • citrate free and contains
    • sucrose (80 mg/mL) as the tonicity agent.1

The original formulation contains

  • sodium citrate dihydrate (5.11 mg/mL) and
  • citric acid anhydrous (0.51 mg/mL) as buffers and
  • sodium chloride (11.69 mg/mL) as the tonicity agent.1 

The ingredients are the same for both the pre-filled pen and syringe.1 Please also see  All Taltz ingredients for all ingredients.  

This medicinal product contains less than 1 mmol sodium (23 mg) per 80 mg dose, that is to say essentially “sodium-free”.2

Ixekizumab is contraindicated in patients with serious hypersensitivity to the active substance or to any of the excipients.2

 All Taltz ingredients 1


Original Formulation

New Citrate-free Formulation

Purpose of Ingredient

Ixekizumab (active ingredient)

80 mg

80 mg

Active ingredient

Polysorbate 80

0.30 mg

0.30 mg


Sodium citrate dihydrate

5.11 mg



Citric acid anhydrous

0.51 mg



Sodium chloride

11.69 mg


Tonicity agent



80 mg

Tonicity agent/ stabilizer

Sodium hydroxide


q.s. to pH 5.7

pH adjustment

Water for injection

q.s. to 1.0 mL

q.s. to 1.0 mL

Solvent/ vehicle

Abbreviations: q.s. = quantity sufficient


1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland

Date of Last Review: 08 December 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request